Sigma-Aldrich Licenses from NeuroSurvival Technologies a Marker for Molecular Imaging of Apoptosis in Vivo
News Feb 27, 2008
Sigma-Aldrich™ and NeuroSurvival Technologies Ltd. (NST) announced that they have signed a licensing agreement for a leading marker, developed by NST, for molecular imaging of apoptosis in vitro and in vivo in animals.
The marker, developed by NST, will be manufactured and marketed by Sigma-Aldrich under the commercial name Apo-TRACE™. Apo-TRACE™ is a member of a family of proprietary small molecules developed by NST that target apoptosis. Another molecule of the family, ApoSense™-PET, is in clinical trials for imaging apoptosis in vivo in humans with PET (positron emitting tomography) and is not part of this agreement.
Apoptosis (programmed cell death) is a fundamental biological process of cell "suicide", inherent in every cell in body, and its discovery is regarded as one of the major recent revolutions in biology and medicine. Apoptosis has an important role in almost any medical disorder, and its control may hold the promise for substantial advances in medical care for a wide array of medical disorders, ranging from cancer, myocardial infarction and cerebral stroke, to neurodegenerative disorders such as Alzheimer's disease.
Source of a Potent Greenhouse Gas IdentifiedNews
A study of a Lake Erie wetland suggests that scientists have vastly underestimated the number of places methane-producing microbes can survive—and, as a result, today’s global climate models may be misjudging the amount of methane being released into the atmosphere.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE